Adding IL-2 to tebentafusp for advanced eye cancer
Treatments studied
Part of Cancer, Eyes & vision clinical trials.
This trial tests if adding another drug called IL-2 to tebentafusp can help stop cancer from growing in people with advanced melanoma that started in the eye (uveal melanoma). It is for those whose cancer got worse while on tebentafusp alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced melanoma that started in the eye (uveal melanoma) that cannot be removed by surgery or has spread.
- You have a specific genetic marker called HLA-A*02:01 (a blood test will check this).
- You are well enough to be up and about (ECOG score 0 or 1).
- Your cancer got worse while you were taking tebentafusp, and you have not had any other cancer treatment in between.
- You do not have untreated or active brain metastases, and you are not taking high-dose steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (tebentafusp and a liver-directed treatment called LDT) for people with uveal melanoma that has spread to the liver. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests a new drug called tebentafusp for people with uveal melanoma that has spread to other parts of the body and who have not yet received any treatment for the metastatic disease. It requires a specific genetic marker (HLA-A*0201) and focuses on whether the drug can shrink or slow the growth of tumors.
This trial tests a new drug called tebentafusp given after standard treatment (surgery or radiation) for high-risk uveal melanoma that hasn't spread. The goal is to see if it helps prevent the cancer from coming back.
This trial tests a two-part treatment for uveal melanoma that has spread to the liver. First, you get a liver-directed chemotherapy (melphalan) through a special procedure called PHP, then you receive an immunotherapy drug (tebentafusp) that helps your immune system attack the cancer.
This trial tests whether combining a drug called tebentafusp with a procedure called radioembolization can help control uveal melanoma that has spread mainly to the liver. Radioembolization delivers tiny radioactive beads to the liver, and tebentafusp helps your immune system attack the cancer.
This trial tests if immune cells taken from a liver tumor can be given back to fight metastatic melanoma. It is for people with stage IV uveal or cutaneous melanoma that has worsened after standard treatments.
Hear when a new Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.